Ketamine does carry a real potential for addiction, but the risk is substantially lower when it’s used in supervised clinical settings at therapeutic doses for depression. The antidepressant dose is a fraction of what recreational users take, sessions are spaced weeks apart, and the medication is administered under direct medical observation. That said, ketamine interacts with the brain’s reward and opioid systems, and some people are more vulnerable to misuse than others.
How Ketamine Works in the Brain
Ketamine’s antidepressant effect has traditionally been attributed to its ability to block a specific type of receptor involved in nerve cell signaling, called the NMDA receptor. Blocking these receptors triggers a cascade that helps nerve cells form new connections, which appears to rapidly lift depression in ways that conventional antidepressants don’t.
But newer research suggests the picture is more complicated. A 2025 review in pharmacology literature argues that ketamine’s effects should be understood as involving both NMDA receptors and the brain’s opioid system, working together. This dual action is part of what makes ketamine so fast-acting for depression. It’s also part of what gives it addictive potential: the opioid system is the same reward pathway activated by drugs like morphine and heroin, though ketamine engages it differently and far less intensely at clinical doses.
Therapeutic Doses vs. Recreational Doses
The standard antidepressant dose of ketamine is 0.5 mg/kg delivered intravenously over 40 minutes. For a 70 kg (154 lb) person, that’s about 35 mg. Recreational users, by contrast, typically take far more: 1 to 2 mg/kg intravenously, 100 to 500 mg orally, or 30 to 400 mg snorted. The therapeutic dose produces a peak blood concentration that’s well below the threshold associated with the dissociative “high” that recreational users seek.
Doses as low as 0.1 mg/kg have shown some antidepressant effect in studies, meaning clinical treatment operates at the very bottom of ketamine’s active range. This matters because addiction risk scales with dose, frequency, and the intensity of the subjective experience. The lower the dose and the less euphoria involved, the less the brain’s reward circuits are reinforced.
How Clinical Protocols Limit Risk
Clinical ketamine for depression follows a carefully spaced schedule. A typical maintenance protocol involves an initial series of three infusions over about a week, then gradually extends to one infusion every two weeks. This spacing is based on research showing the median time before a single dose wears off is roughly 18 days. Some patients have maintained this every-two-to-four-week schedule for three years or longer without safety issues emerging.
The FDA-approved nasal spray version, esketamine (sold as Spravato), adds additional layers of control. It carries a boxed warning for abuse and misuse potential and is only available through a restricted program. Patients must take each dose in a certified healthcare setting and remain under observation for at least two hours afterward. They cannot take the medication home. This structure is specifically designed to prevent the kind of unsupervised, escalating use that leads to dependence.
Before starting treatment, clinicians typically screen patients for substance use history. Validated tools like the Ketamine Side Effect Tool help flag individuals who may be at higher risk for misuse, allowing providers to weigh benefits against that risk on a case-by-case basis.
What Tolerance Looks Like
Tolerance, where the same dose produces a weaker effect over time, is one of the early steps on the road to dependence. With ketamine for depression, tolerance can develop if doses are given very frequently, but experts note this is mainly a concern with unrestricted, on-demand use rather than the controlled schedules used in clinical practice. Clinicians who have treated patients for years at standard intervals report that dose escalation has not been necessary.
That said, some patients do find that a single infusion doesn’t produce a lasting effect, and a second session is often needed to determine whether someone will respond at all. If two infusions at the standard dose don’t help, higher doses are unlikely to work either. This built-in ceiling reduces the temptation to keep increasing the amount.
What Dependence and Withdrawal Feel Like
Most of what we know about ketamine dependence comes from studies of heavy recreational users, not clinical patients. Among people who develop ketamine use disorder, the physical toll is significant: 60% report bladder problems, 60% develop nasal damage (from snorting), and 56% experience intense abdominal cramping known as “K-cramps.”
When regular heavy users stop, withdrawal symptoms include cravings (reported by 71%), low mood (62%), anxiety (59%), and irritability (45%). Additional symptoms can include fatigue, sleep disturbances, shaking, heart palpitations, and in some cases, delusions. Researchers have noted these symptoms resemble a mild version of opioid withdrawal, which aligns with the understanding that ketamine engages the brain’s opioid pathways.
These withdrawal profiles come from people using ketamine at recreational doses, often daily. There is no comparable body of evidence showing that patients on supervised, low-dose maintenance protocols develop this kind of physical dependence. The gap between clinical and recreational exposure is large enough that the experiences are difficult to compare directly.
Who Faces Higher Risk
The people most likely to develop problematic ketamine use are those with a history of substance use disorders, particularly involving opioids, alcohol, or other dissociative drugs. The dissociative and mildly euphoric effects of ketamine, even at clinical doses, can be appealing to individuals prone to chasing altered states. A personal or family history of addiction is the single most important risk factor clinicians look for before prescribing.
Access also shapes risk. Patients receiving IV infusions in a clinic every two weeks have limited opportunity for misuse. Patients receiving at-home oral ketamine prescriptions through telehealth services, which have grown rapidly in recent years, face fewer structural guardrails. The more control a patient has over their own dosing, the more the risk profile shifts toward that of recreational use. If you’re considering ketamine treatment, the setting and supervision matter as much as the drug itself.
The Bottom Line on Addiction Risk
Ketamine is not a benign substance. It activates reward pathways, produces noticeable psychological effects, and can cause dependence with heavy use. But the version of ketamine used to treat depression looks very different from the drug used recreationally. The doses are lower, the frequency is tightly controlled, and in most clinical settings, you never handle the medication yourself. For most patients without a significant substance use history, the addiction risk of supervised ketamine therapy is low, though it is never zero.